May 19, 2011 - BridgePoint Medical Inc. has announced that they have received clearance of an expanded indication for the CrossBoss Catheter and Stingray System from the U.S. Food and Drug Administration (FDA). The expanded indication includes the intraluminal placement of conventional guidewires beyond stenotic coronary lesions [including chronic total occlusions (CTOs)] prior to PTCA or stent intervention. CTOs are chronically stenosed lesions that completely block a coronary artery – typically for 3 months or longer – and prevent blood circulation to critical areas of the heart. This expanded indication is the result of data generated from the 147-patient FAST-CTOs clinical trial in which the safety and effectiveness of the system in coronary chronic total occlusions was demonstrated. William Lombardi, M.D., of St. Joseph's Hospital in Bellingham, Wash., and a leading enroller in the clinical trial states, "The BridgePoint system is the first set of devices designed specifically for treating coronary CTOs that has shown real improvements in safety, procedural efficiency, and clinical success rates. The clinical trial has proven that these arteries can be opened effectively with these products and now with the expanded indication from the FDA there will be a new level of awareness among physicians and patients." BridgePoint's ability to commercialize its CrossBoss Catheter and Stingray System will be greatly expanded with this new level of indication. BridgePoint is the first interventional device company to be granted this specific type of approval for both crossing and re-entry technologies to be used in the treatment of coronary CTOs. For more information: www.bridgepointmedical.com
If you enjoy this content, please share it with a colleague
FDA Expands Indication for CrossBoss, Stingray to Treat CTOs
Related Content
April 3, 2024 — The U.S. Food and Drug Administration (FDA) announced that Teleflex and Arrow International are ...
December 5, 2022 — The U.S. Food and Drug Administration (FDA) is alerting health care facilities and providers of a ...
According to a new report from Allied Market Research, the global catheters market was valued at $22.7 billion in 2021 ...
May 10, 2022 — The MIVI Neuroscience Q Aspiration Catheter incorporates a novel pusher wire design on its proximal end ...
February 9, 2022 — Innovative Health, LLC, a specialty cardiology reprocessor, has announced that the company has ...
October 23, 2019 — BioCardia announced the U.S. commercial availability of its Avance Bi-Directional Steerable ...
August 23, 2019 — Cook Medical recently released the second generation of the 2.6 Fr CXI Support Catheter with platinum ...
May 16, 2019 — BioCardia Inc. announced U.S. Food and Drug Administration (FDA) 510(k) clearance of the Avance steerable ...
February 21, 2019 — Navitian, the new coronary microcatheter from iVascular, recently received CE mark approval. The ...